Literature DB >> 2858217

Interaction of propoxyphene with diazepam, alprazolam and lorazepam.

D R Abernethy, D J Greenblatt, D S Morse, R I Shader.   

Abstract

Healthy volunteers received single doses of three benzodiazepines (diazepam, 10 mg i.v.; alprazolam, 1.0 mg orally; lorazepam, 2 mg i.v.) on two occasions in random sequence. One trial was a control; for the other, subjects ingested propoxyphene, 65 mg every 6 h, for the duration of the benzodiazepine study. The kinetics of each benzodiazepine were determined from multiple plasma concentrations measured following each dose. For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1). Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005). Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1). Thus propoxyphene significantly impairs the clearance of alprazolam, biotransformed mainly by the oxidative reaction of aliphatic hydroxylation. Propoxyphene has far less effect on the oxidation of diazepam by N-demethylation, and has no apparent influence on lorazepam conjugation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858217      PMCID: PMC1463783          DOI: 10.1111/j.1365-2125.1985.tb02612.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

Authors:  D J Greenblatt; K Franke; R I Shader
Journal:  J Chromatogr       Date:  1978-09-01

2.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.

Authors:  D J Greenblatt; R I Shader; K Franke; D S MacLaughlin; J S Harmatz; M D Allen; A Werner; E Woo
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

Review 3.  Biochemical and genetic factors regulating dilantin metabolism in man.

Authors:  H Kutt
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

4.  Automated gas chromatographic determination of plasma alprazolam concentrations.

Authors:  D J Greenblatt; M Divoll; R I Shader
Journal:  J Clin Psychopharmacol       Date:  1983-12       Impact factor: 3.153

Review 5.  Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; H R Ochs; R I Shader
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

6.  Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

7.  Impairment of hepatic drug oxidation by propoxyphene.

Authors:  D R Abernethy; D J Greenblatt; K Steel; R I Shader
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

8.  Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives.

Authors:  D R Abernethy; D J Greenblatt; H R Ochs; D Weyers; M Divoll; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

9.  Alprazolam kinetics in the elderly. Relation to antipyrine disposition.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; L J Moschitto; R B Smith; R I Shader
Journal:  Arch Gen Psychiatry       Date:  1983-03

10.  Interaction between carbamazepine and propoxyphene in man.

Authors:  M Dam; C B Kristensen; B S Hansen; J Christiansen
Journal:  Acta Neurol Scand       Date:  1977-12       Impact factor: 3.209

View more
  6 in total

Review 1.  Pharmacokinetics of the newer benzodiazepines.

Authors:  P D Garzone; P D Kroboth
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

2.  Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition.

Authors:  R A Robson; J O Miners; A G Whitehead; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

3.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 4.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

5.  [Sustained-release dextropropoxyphene.].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1991-12       Impact factor: 1.107

Review 6.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.